Summit Therapeutics Share Discussion Threads

[freedosh] 10/1/2017 19:54

Rocketing here in NY Don't know why but can't complain!
Perhaps the sell buttons have all frozen.
We actually had a power outage here last night - that didn't even happen on the little Caribbean island I was on until yesterday morning. Talk about Third World.

[waterloo01] 10/1/2017 19:13

Hopefully $10.00 will hold this time. (Up 14% on Nasdaq).

[hugus maximus] 10/1/2017 17:01

Summit value is so clearly wedded to the Sarepta share price ... for the time being!

[hugus maximus] 10/1/2017 17:00

Many thanks Freedosh and Waterloo. Fascinating - a wide series of applications possible but still a comfortable time away. So the microdystrophin gene work also has 15 years of history (but something not quite right when applied to problems with cardiac lesion)

It still amazes me when you see that ground breaking research often falters in the early stages and therefore any success clearly takes years to get into the public domain.

On which note, I find it really encouraging that we've heard nothing negative several months after notification that the first DMD boys have been given doses of Ezutromid in Summit P2 ... this all feels rather good!

[freedosh] 10/1/2017 16:19

As waterloo01 says, years behind.
Could up regulate microdystrophin. AAV vector is not especially efficient but is safe. I worked with it many years ago. Not immunogenic (shouldn't be rejected)but the total construct is novel and therefore might be. Up to 2/3 of humans are immune to AAV but likely lower in this age group. Those who are positive will require plasma exchange to remove antibodies and perhaps immune suppressive drugs during treatment.

Gene therapy using microdystrophin gene itself has been studied (in the mouse) for 15 years. It can correct the cardiac lesion when site directed but that approach appears to have stalled.

Ultimately gene partial excision and insertion of a healthy replacement section will be the cure. Yonks away.
GLA from freezing NY NY

[waterloo01] 10/1/2017 15:50

I see money talks. SRPT (and SMMT) up about 10%

[hugus maximus] 10/1/2017 14:11

Does someone cleverer than I understand Sarepta's "new" research path as following a principle that Summit have been working with for some time? i.e. Summit are already using Utrophin to "perform a similar function as dystrophin" So is the new Sarepta research following that lead ... ?

"Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program"



"The experimental program, explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy. As a “surrogate gene therapy approach”, the gene therapy looks to induce genes that make proteins that can perform a similar function as dystrophin, with the goal of producing a muscle cell that can function normally even when dystrophin is absent. It has the potential to be used broadly in several muscular dystrophies."

[hugus maximus] 10/1/2017 09:41

Zacks suggest a "HOLD" for Summit stocks again:

[waterloo01] 09/1/2017 21:39

John Carol tweet: PTCT sold $81M of Translarna in 2016. Not bad for a drug with no proof of efficacy.

Just wait for one that works!

[waterloo01] 08/1/2017 16:32

I understand I had it wrong about presentations but they are out in force at JPM17 in SF this week (one of the most important of the gatherings in biotech). Let's hope they have some productive meetings.

[hugus maximus] 06/1/2017 15:26

Freemoney ... just joshing. I think many of us anticipate break through news, but know not whence it might come.

It's interesting to remember that Summit's last groundbreaking change of circumstance actually came about as a result of another pharma's success.

Not anticipating ground breaking news with DMD for a wee while and FDX / RIDZ comparison data won't be in just yet.

So I'm sitting here topped up to my limit in the knowledge that the only way is up and a sudden change of circumstance elsewhere, may again be what turns things around next.

"Seeking company with recent cash windfall ... interest in helping folk who hang out in hospitals and catch fatal disease essential ... all offers considered"

[freemoney1] 06/1/2017 14:05

Sorry links to proactive seem to get removed but easy to find on their site.

[freemoney1] 06/1/2017 14:04

Hugus, It was on of his comments in a 2016 interview... I think with Proactive. I don't have time to run through and listen to them now though.

Maybe this one but if not it's worth another listen :-)
[...]

[abergele] 05/1/2017 21:04

A nice run up with no retrace on the day,very nice,thought we were due a follow the nasdac as said last night..could still follow on tomorrow as nasdac SUMM tonight has'nt lost out completely..

[hugus maximus] 05/1/2017 17:10

Freemoney - That's a fascinating notion from Glyn that "there will be a path for shareholders to get their return on Ridinilazole" Is that a 2017 quote?
;-/

[freemoney1] 05/1/2017 16:15

No news flow expected in the near term.... could we expect Director buys then?

Maybe not if they expect to release some news and can actually hit those options targets. I think I'm correct in remembering that the exercise price of the options is only 60p but they need the share price to be over £4 to realise them.

It's all very quiet so I guess we have to make up our own scenarios and guess the next move. All good fun.

Glyn, said there will be a path for shareholders to get their return on Ridinilazole. We're all on the edge of our seats to find out what that is... any clues or updates Summit BoD ?

[chrisatrdg] 05/1/2017 14:44

I agree with the recent posts & especially waterloo01 above & I have also been watching SRPT which I think helped pull up SMMT on NASDAQ which is now being reflected on AIM today.This is when NASDAQ does work for us.

With regards future news flows I agree the triggering of the next SRPT milestone payment will hopefully create some further share price movement upwards.

In addition we will have feeding into the Income Statements for the 12 months to 31st October 2017 the £6.9m deferred income shown under Current Liabilities & then the balance of the £25m for future years shown under Non-current liabilities which will also help the Income Statements.

For me it is all good news.

PS Sitting at home post knee surgery Tuesday resting & enjoying all the posts - Thank You.

[waterloo01] 05/1/2017 09:04

tightfist, could be a number of things. EZD recruitment aside (and the issue isn't getting the boys - they have more already 'signed up' than needed but trial centres ability to process them), by June they really have to ink a deal on RDZ if they want to get a phase 3 going in 17 (which they do).

Director buys/II buying/patient noise/pressure re DMD or something left field (the SRPT deal being one of those) or just as we get closer to EZD results.

I suspect SRPT will start to recover as patients get recruited and money flows and we should see a bump on the back of it, so a number of potential movers IMO.

[tightfist] 05/1/2017 08:55

Waterloo,I too am thinking about potential, predictable positive news flow over the next few months. The one that comes to mind is the first dosing of the last patient in the U.S. EZD trial - and triggering the next SRPT milestone payment. Other than that does the cupboard look a little bare until around June?Of course, other events may happen (good and not so good) and there may be increasing awareness through conferences, etc. And renewed interest in targeted antibiotics.Just musing too!

[abergele] 05/1/2017 08:04

Yes I agree Tf,,,it's surely our turn for a lift next,
obviously extra purchases need to happen first to squeeze the m/m's upwards,,,gla

[tightfist] 05/1/2017 07:52

A nice little kick-up last night on the Nasdaq chart, starting to push-back on the 3 month downtrend. Hopefully the start of a better 3 months....... On LSE as well as Nasdaq!

[abergele] 04/1/2017 20:30

Hugus,,,,we are too reserved this side of the pond,,or bloody stupid,,

If we could get some buying interest again,and momentum getting us to £1.55
we can have a break above 25 dma's, we are over the 100 dma,but the 50 dma is the big obstackle at the high £1.60's...

nothing has changed,no bad news,,so why are we down except that we followed that blessed nasdac prices.....gla